Clinical Trials
75 trialsNCT07407803 2026-05-27
Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Recruiting
NCT04305470 2026-05-18
MEN-301
NX Development Corp
Phase 3 Completed
NCT04739761 2026-05-12
DESTINY-B12
AstraZeneca
Phase 3 Active not recruiting
NCT06556563 2026-05-01
EF-41
NovoCure Ltd.
Phase 3 Recruiting
NCT07195591 2026-04-30
BRIDGES
GT Medical Technologies, Inc.
Phase 3 Recruiting
NCT05902169 2026-04-24
SONOBIRD
CarThera
Phase 3 Recruiting
NCT05317858 2026-04-16
LIMITLESS
InSightec
Phase 3 Recruiting
NCT05580562 2026-04-16
ACTION
Jazz Pharmaceuticals
Phase 3 Recruiting
NCT07100730 2026-04-16
IPAX BrIGHT
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT06496971 2026-04-09
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of AvastinĀ® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
NaviFUS Corporation
Phase 3 Recruiting
NCT04724369 2026-04-03
Open-Label Study of 18F-mFBG for Imaging Neuroblastoma
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Phase 3 Active not recruiting
NCT04924608 2026-03-23
KOMET
AstraZeneca
Phase 3 Active not recruiting
NCT05303519 2026-03-05
SIGMA
Nuvation Bio Inc.
Phase 3 Recruiting
NCT06057168 2026-01-29
GDX-44-016
Guerbet
Phase 3 Completed
NCT02831959 2025-10-31
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
NovoCure Ltd.
Phase 3 Completed
NCT00807027 2025-10-10
Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea
GC Cell Corporation
Phase 3 Completed
NCT04365374 2025-10-07
Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
GT Medical Technologies, Inc.
Phase 3 Active not recruiting
NCT04674683 2025-09-24
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
HUYABIO International, LLC.
Phase 3 Active not recruiting
NCT03149575 2025-09-04
STAR-3
Kintara Therapeutics, Inc.
Phase 3 Terminated
NCT04410133 2025-08-28
REVELATE
Blue Earth Diagnostics
Phase 3 Completed
NCT02667587 2025-06-18
CheckMate548
Bristol-Myers Squibb
Phase 3 Completed
NCT03632135 2025-04-15
CSCRGBM
Cordgenics, LLC
Phase 3 Completed
NCT02017717 2025-04-04
CheckMate 143
Bristol-Myers Squibb
Phase 3 Completed
NCT04164901 2025-04-03
Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
Servier
Phase 3 Active not recruiting
NCT05913037 2025-03-06
FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 3 Active not recruiting
NCT05118776 2024-10-31
Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM
Ascletis Pharma Inc
Phase 3 Active not recruiting
NCT03776071 2024-04-22
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
Denovo Biopharma LLC
Phase 3 Completed
NCT02546102 2024-04-03
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
Precision Life Sciences Group
Phase 3 Suspended
NCT03149003 2023-11-15
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT02573324 2023-05-11
Intellance1
AbbVie
Phase 3 Completed
NCT03613181 2023-04-24
ANGLeD
Angiochem Inc
Phase 3 Unknown
NCT02617589 2023-03-28
CheckMate 498
Bristol-Myers Squibb
Phase 3 Completed
NCT03710564 2023-01-30
MERLIN
Novartis
Phase 3 Terminated
NCT02201381 2022-07-18
METRICS
Health Clinics Limited
Phase 3 Withdrawn
NCT04461886 2022-05-24
A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I
Nobelpharma
Phase 3 Terminated
NCT00045968 2022-05-18
GBM
Northwest Biotherapeutics
Phase 3 Unknown
NCT02796261 2022-01-21
STELLAR
Orbus Therapeutics, Inc.
Phase 3 Unknown
NCT00005887 2021-08-23
Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases
Spectrum Pharmaceuticals, Inc
Phase 3 Completed
NCT03393000 2021-07-22
INTACT
Diffusion Pharmaceuticals Inc
Phase 3 Terminated
NCT03419403 2021-04-14
UNITE Study: Understanding New Interventions With GBM ThErapy
AbbVie
Phase 3 Terminated
NCT04277221 2020-03-17
ADCTA for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM)
Safe Save Medical Cell Sciences & Technology Co.,Ltd.
Phase 3 Unknown
NCT00295815 2019-09-12
Enzastaurin Versus Lomustine in Glioblastoma
Eli Lilly and Company
Phase 3 Completed
NCT04058704 2019-08-15
SMART
Betta Pharmaceuticals Co., Ltd.
Phase 3 Unknown
NCT00126412 2019-05-31
Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma
GE Healthcare
Phase 3 Completed
NCT00820222 2019-04-02
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
Novartis
Phase 3 Completed
NCT02511405 2018-10-23
GLOBE
Vascular Biogenics Ltd. operating as VBL Therapeutics
Phase 3 Completed
NCT01480479 2018-01-16
ACT IV
Celldex Therapeutics
Phase 3 Completed
NCT00943826 2017-09-25
A Study of Bevacizumab (AvastinĀ®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
Hoffmann-La Roche
Phase 3 Completed
NCT00522951 2017-08-28
SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study
Bayer
Phase 3 Completed
NCT00335075 2017-05-15
Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)
Merck Sharp & Dohme LLC
Phase 3 Completed